Age: 82.0
Sex: M
Vaccine: COVID19, COVID19
Symptoms: Muscular weakness, Oedema peripheral
Clinical narrative: Dose number 3; some difficulty communicating and comprehension and short term forgetting resulting in loss of cell phone and whether wife had taken her cancer medicine; some difficulty communicating and comprehension and short term forgetting resulting in loss of cell phone and whether wife had taken her cancer medicine; some difficulty communicating and comprehension and short term forgetting resulting in loss of cell phone and whether wife had taken her cancer medicine; Severe pitting edema in both ankles; Muscle weakness in both legs; fatigued; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 82 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 08Nov2021 10:15 (Lot number: Fj1611) at the age of 82 years as dose 3 (booster), single for covid-19 immunisation. Relevant medical history included: "Hypoglycemia" (unspecified if ongoing); "spinal stenosis" (unspecified if ongoing). Concomitant medication(s) included: TAMSULOSIN HCL. Past drug history included: Sulphur, reaction(s): "Allergy: Sulphur", notes: known allergies: Sulphur. Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: Ew0172, Location of injection: Arm Left, Vaccine Administration Time: 10:15 AM), administration date: 01May2021, when the patient was 81 years old, for Covid-19 Immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: Er8734, Location of injection: Arm Left, Vaccine Administration Time: 02:00 PM), administration date: 04Apr2021, when the patient was 81 years old, for Covid-19 Immunization. The following information was reported: IMMUNISATION (medically significant) with onset 08Nov2021 10:15, outcome "unknown", described as "Dose number 3"; MENTAL IMPAIRMENT (medically significant), COMMUNICATION DISORDER (non-serious), MEMORY IMPAIRMENT (non-serious) all with onset Nov2021, outcome "not recovered" and all described as "some difficulty communicating and comprehension and short term forgetting resulting in loss of cell phone and whether wife had taken her cancer medicine"; OEDEMA PERIPHERAL (non-serious) with onset Nov2021, outcome "not recovered", described as "Severe pitting edema in both ankles"; MUSCULAR WEAKNESS (non-serious) with onset Nov2021, outcome "not recovered", described as "Muscle weakness in both legs"; FATIGUE (non-serious) with onset Nov2021, outcome "not recovered", described as "fatigued". The events "some difficulty communicating and comprehension and short term forgetting resulting in loss of cell phone and whether wife had taken her cancer medicine", "some difficulty communicating and comprehension and short term forgetting resulting in loss of cell phone and whether wife had taken her cancer medicine", "some difficulty communicating and comprehension and short term forgetting resulting in loss of cell phone and whether wife had taken her cancer medicine", "severe pitting edema in both ankles", "muscle weakness in both legs" and "fatigued" were evaluated at the physician office visit. Therapeutic measures were taken as a result of mental impairment, communication disorder, memory impairment, oedema peripheral, muscular weakness, fatigue. Clinical course: Severe pitting edema in both ankles,  Muscle weakness in both legs, some difficulty communicating and comprehension and short term forgetting resulting in loss of cell phone and whether wife had taken her cancer medicine,  fatigued. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient  had not been tested for COVID-19. Concomitant medications: Tamsulosin Hal 0.4 mg cap, areas 2, alive men's 50. Treatment received for the adverse event was Furosemide 40 mg tab.